Ipca Laboratories Reports Consolidated Growth, Drives Margin Improvement in Q4 FY26

Ipca Laboratories Reports Consolidated Growth, Drives Margin Improvement in Q4 FY26​

Ipca Laboratories Ltd has reported consolidated growth and significant margin improvements for the fourth quarter of fiscal year 2025-2026 (Q4 FY26), alongside strong performance indicators across its major business segments. The company's overall business size continued to grow, supported by robust growth in generic and promotional branded export businesses.

The consolidated business grew by approximately 6% to stand at around INR1,396 crores, up from INR1,266 crores in the previous financial year (FY26). For the full fiscal year March 2026, the consolidated revenue saw an increase of about 8%, reaching INR9,646 crores compared to INR8,940 crores.

Business Segment Performance​

Ipca Laboratories showcased varying performance across its core segments:

• Generic Business: Excluding tenders, the generic business delivered impressive growth of around 17% for the financial year, rising from INR982 crores in FY25 to approximately INR1,149 crores.
• Domestic Formulation: The domestic formulation segment grew by about 12%. Q4 FY26 performance was reported at INR853 crores, up from INR764 crores recorded in Q4 of the previous year. The market share for Ipca in this area marginally improved to 2.09%, increasing slightly from 2.08% in December 2025.
• Institutional Business: This division experienced a decline during the financial year, with revenue falling to approximately INR270 crores from around INR355 crores in the prior financial year. In Q4 of the current year, business declined to about INR74 crores compared to INR111 crores in Q4 FY25.
• API Business: The API segment delivered a growth rate of around 10% for the entire year.

Margin and Cost Management Focus​

The company reported notable increases in margins across various levels of operation. Stand-alone EBITDA margins improved by approximately 25.27% in Q4, compared to 21.19% in Q4 FY25, representing an improvement of nearly 4.08%. For the full financial year March 2026, the stand-alone EBITDA margin increased to about 25.18%, up from 22.66% in March '25, signaling a significant positive movement against internal guidelines.

Consolidated Q4 FY26 EBITDA margin improved by around 20.52%, up from 18.24% in Q4 FY25. For the entire fiscal year, consolidated EBITDA margins reached 20.72%, compared to 19.94% in March '25, meeting the company's target of 20% for FY26 overall.

Regarding operational costs and input prices, management noted that the material cost has declined by around 2% based on a cash stand-alone basis, while input price issues persist in certain areas. Packaging material, aluminum, PVC, and PVDC have seen significant price increases. Furthermore, solvent prices remain between 40% to 50% higher than those recorded in January or earlier in the fiscal year.

To offset these rising costs, a price increase of around 6% to 7% is planned for non-price controlled domestic products. For generic markets, long term arrangements are being made with buyers to increase prices where possible.

International and Subsidiary Business Updates​

The US market segment (combining Ipca USA and Unichem USA) showed solid growth. Q performance in the US was approximately INR428 crores against INR388 crores in Q4 of the previous year, reflecting a 10% increase. For the full financial year, the US business grew by around 14%, reaching INR1,567 crores from INR1,379 crores last year.

Looking ahead, management projected that markets such as India will grow at 12% to 13%, CIS market at 10% to 11%, and overall generic markets at 12% to 13%.

The US business is expected to maintain a strong trajectory; Unichem’s U.S. segment is anticipated to achieve an EBITDA margin of 12% to 13% in the current year, up from previous levels.

Key subsidiary updates include:

• Trophic Wellness: This domestic subsidiary contributed positively with a business turnover of around INR125 crores and generated a profit of almost INR40 crores.
• Krebs Bio: The plant located in Nellore has achieved EBITDA positive status, while concerns remain regarding the polishing departments at other plants.
• International Subsidiaries: Ipca Formulation Marketing Company, which serves the UK market, recorded a loss estimated between 2 million to 3 million, largely due to challenging pricing scenarios in the previous financial year. Onyx Scientific faces some operational difficulties as inquiry levels for its research services have declined but signs of improvement are currently being observed.

The company's overall material cost to sales ratio stands at 25%, a figure management stated is robust enough to absorb price increases while maintaining profitability across domestic and international products.

IPCALAB Stock Price Movement​

IPCA Laboratories Limited edged higher in trading today, with shares rallying to settle at ₹1590.3, recording a 2.29% gain on the close. The equity traded within a strong intraday range, moving from a low of ₹1538.1 to a high of ₹1605.